Makhzan Ali Akbar

Makhzan Ali Akbar

Auto-generated profile, based on publicly available information

Makhzan Ali Akbar

North Sichuan Medical College

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
MAMakhzan Ali Akbar
Makhzan Ali Akbar
MMMeer Murtaza
Meer Murtaza
FMFakhar e Mahin
Fakhar e Mahin
HAHasibullah Aminpoor
Hasibullah Aminpoor
Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited. To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris. This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity. A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18). Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.

15 July 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
RFRamzan Farooq
Ramzan Farooq
MAMakhzan Ali Akbar
Makhzan Ali Akbar
AAAlisha Ahmed
Alisha Ahmed
HAHasibullah Aminpoor
Hasibullah Aminpoor
Background: Cutaneous aging is characterized by progressive degradation of the extracellular matrix, manifesting as diminished hydration, loss of elasticity, and increased wrinkle depth. While oral hydrolyzed collagen peptides (HCPs) are increasingly utilized as systemic nutricosmetics, previous evidence syntheses have been limited by severe methodological heterogeneity and the inability to account for highly influential statistical outliers. This updated systematic review and meta‐analysis evaluated the clinical efficacy of oral collagen peptides for skin rejuvenation using an advanced statistical framework. Methods: A comprehensive literature search was conducted on PubMed (MEDLINE), Cochrane Library, and Google Scholar from inception to November 2025. Randomized controlled trials evaluating oral collagen supplementation in healthy adults were included. Data were synthesized using random effect models. To differentiate true clinical signals from statistical artifacts, analyses were reinforced with multilevel meta‐analysis, leave‐one‐out sensitivity testing, and dose–response spline regressions. Results: Thirty‐five randomized controlled trials comprising 2534 participants were included. Primary analysis revealed that oral collagen supplementation yielded statistically significant improvements in instrumental measures of skin hydration (SMD = 0.44; 95% CI: 0.15–0.73), skin elasticity (SMD = 0.62; 95% CI: 0.15–1.10), and barrier function via reduced transepidermal water loss (SMD = −0.39; 95% CI: −0.62 to −0.16). Efficacy appeared predominantly time‐dependent rather than dose‐dependent, with elasticity and barrier improvements requiring at least 12 weeks of supplementation. Conversely, rigorous sensitivity and multilevel analyses demonstrated that apparent improvements in structural parameters, specifically skin wrinkles, roughness, and dermal density, were statistical artifacts driven by high‐leverage outliers and severe inter‐study heterogeneity. Conclusion: Oral collagen peptide supplementation is an effective functional systemic moisturizer that produces significant time‐dependent improvements in cutaneous hydration, elasticity, and barrier retention. However, current evidence from trials of standard duration remains limited and inconsistent regarding structural anti‐aging effects, including macroscopic wrinkle reduction and dermal densification, and the existing data are simply not robust enough to support definitive conclusions in these domains.

25 May 2026 in Future Cardiology
Verified
Journal Article
Closed access
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
ABAsia Batool
Asia Batool
MHMuhammad Hussain
Muhammad Hussain
MHMuhammad Hassan
Muhammad Hassan
ASAsharib Sohaib
Asharib Sohaib
AHAbdul Hannan
Abdul Hannan
1. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, with dyslipidemia being an important modifiable risk factor [1]. Elevated low-density lipoprotein cholestero...

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
MAMakhzan Ali Akbar
Makhzan Ali Akbar
MMMeer Murtaza
Meer Murtaza
AAAshfaq Ahmad
Ashfaq Ahmad
HAHasibullah Aminpoor
Hasibullah Aminpoor
Background: Scabies is an infectious parasitic integumentary pathology affecting both pediatric and adult participants globally, specifically in resource‐limited settings. Topical permethrin is commonly advised as the preferred regimen, whereas oral and topical ivermectin have emerged as alternative regimens. Objective: This study aims to assess the safety and efficacy of oral or topical ivermectin compared to topical permethrin alone for the treatment of scabies in both pediatric and adult patients. Methods: A systematic search of four databases (PubMed, Google Scholar, Scopus, and Embase) was conducted from inception to November 2025. Data were analyzed using a random‐effects model (REML estimator) to calculate risk ratios (RRs) and mean differences. To prevent unit‐of‐analysis errors, overarching estimates utilized deduplicated data. Advanced influence diagnostics (leave‐one‐out sensitivity, Baujat plots, and GOSH plots) were employed to rigorously evaluate data stability and outcome fragility. Results: In this meta‐analysis, 38 studies met the inclusion criteria, encompassing 5604 participants. Permethrin demonstrated a robust and highly significant early clinical cure advantage over ivermectin at Week 1 (RR 1.40; 95% CI 1.22–1.62; p < 0.0001; I 2 = 81.1%). While permethrin maintained a marginal statistical superiority at Week 2 (RR 1.11; 95% CI 1.01–1.22), extensive sensitivity analyses revealed this finding to be highly fragile and dependent on outliers. By Weeks 3, 4, and ≥ 6 , comparative efficacy converged, demonstrating no significant difference between the two treatments (RR 1.02 at ≥ 6 weeks; I 2 = 0%). Continuous meta‐regression indicated no significant temporal shift in comparative efficacy over the last 25 years. Conclusion: Low‐to‐moderate certainty evidence suggests that permethrin exhibits superior acute efficacy and faster initial clearance during the first week of treatment compared to ivermectin. However, long‐term efficacy is equivalent. Ivermectin remains a highly viable and equally effective alternative for the definitive management of scabies, particularly when topical application is infeasible or poorly tolerated.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
SKSaifullah Khan
Saifullah Khan
AAAlisha Ahmad
Alisha Ahmad
AAAiza Ahsan
Aiza Ahsan
EJEvardo Barros de Deus Nunes Junior
Evardo Barros de Deus Nunes Junior
Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.